Objective: We evaluated contemporarily serum alpha and beta chemokines in patients with newly diagnosed systemic sclerosis (SSc) in the presence or absence of autoimmune thyroiditis (AT).
Methods: Serum levels of CXCL10 and CCL2 chemokines, prototypes of the 2 major subclasses (Th1 and Th2), were measured in patients with newly diagnosed SSc with (n = 40; SSc-II) or without (n = 50; SSc-I) AT, in comparison with 50 normal controls (control-I) and 40 AT controls without SSc (control-II) (sex- and age-matched).
Results: Serum CXCL10 levels were significantly higher in control-II, SSc-I, and SSc-II than in control-I (150 +/- 131, 196 +/- 137, 254 +/- 98, 83 +/- 42 pg/ml, respectively; p < 0.001 for all). SSc-I had serum CXCL10 levels significantly higher than control-II (p = 0.03), and significantly lower than SSc-II (p = 0.04). SSc-II had serum CXCL10 levels significantly higher than control-II (p = 0.002). Serum CCL2 levels were significantly higher in SSc-I and SSc-II than in control-I (378 +/- 192, 403 +/- 131, 316 +/- 113 pg/ml, respectively; p = 0.03 and p < 0.01, respectively). SSc-II had serum CCL2 levels significantly higher than control-II (327 +/- 123 pg/ml; p = 0.04).
Conclusion: Our study demonstrates high serum levels of both CXCL10 (Th1) and CCL2 (Th2) chemokines in patients with SSc, and suggests a prevalence of Th1 immune response in the early phase of the disease. A further increase of serum CXCL10, but not of CCL2, is observed in SSc patients with AT.